EGFR and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), however, the clinical utility of ctDNA has been limited to detecting mutations in the genes that encode druggable proteins such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK).